Soligenix, Inc. announced on November 14, 2024, that it has opened patient enrollment for its Phase 2 study (DUS-AUBD-01) evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease. This marks a significant step in expanding the development of dusquetide into innate immune-related inflammatory conditions.
The open-label pilot clinical trial is designed to enroll approximately 25 patients aged 18 years or older with mild to moderate Behçet's Disease and active oral and/or genital ulcers. Patients will receive SGX945 as a twice-weekly intravenous infusion for four weeks, followed by four weeks of follow-up.
The company anticipates completing enrollment and announcing top-line study results in the first half of 2025. Behçet's Disease represents an area of unmet medical need, affecting up to 1 million people worldwide, and SGX945 aims to offer significant relief to these underserved patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.